Presently, BPC 157 therapy has still limited but encouraging clinical evidence (no toxicity in clinical trials (i.e., effective in ulcerative colitis, phase II) and toxicology studies without lethal dose (LD1)), and much more should be further achieved [1,2,3,4,5,6,7,8,9,10,11]
Early animal studies suggest possible roles in wound healing and gut protection
1995.) has shown that BPC 157 did not display any pharmacological affinity for any of the receptor systems studied
Possible Mild Reactions Redness Itching Minor irritation at the application site These are generally transient and resolve on their own
Likewise, for bone morphogenic proteins (BMPs), at that time, besides bone matrix, the following biomaterials have been tested as carriers: calcium phosphate, collagen, gelatin, and starch (Urist, 1996) is true also nowadays, and it can be generally applied to any of the peptide + carrier complexes
Why Does GHK-Cu Sting on Injection